The effect of N-cadherin antagonists will likely be influenced by many variables including: the repertoire of CAMs (e.g., integrins, nectins) expressed by a particular cell type, method of administration, dosing schedule, tumor size and type, pericyte coverage of the endothelium, and growth factor (e.g., VEGF) levels. The gene discussed is CDH2; the disease is neoplasm.